Less than two years after the murder of its founder and with a possible sale in the works, Apotex has lost FDA approvals for 31 of its drugs.
An FDA warning letter for Akorn's New Jersey plant acknowledges efforts by management to turn things around but says it is not nearly enough.
Even as GlaxoSmithKline has opened its most advanced manufacturing site in Asia, it is selling an older plant in China to Fosun Pharma.
The FDA has noted a dozen issues at the facilities where Biocon will make the Lantus copycat that it will share with Mylan.
Teva has sold a manufacturing plant and its U.S. portfolio of OTC products to a family-owned company that is all about store brands.
GlaxoSmithKline has opened continuous manufacturing operations in Singapore that will make products faster, with less cost and less waste.
India’s Aurobindo has been savaged in an FDA warning letter for missteps that paved the pathway to the valsartan mess.
Amicus Therapeutics has struck a deal for the gene therapy units of Thermo Fisher and Catalent to handle its manufacturing.
Lonza is buying a sterile manufacturing and fill-and-finish facility in Stein, Switzerland, from Novartis that is only 10 years old.
Just months after Catalent jumped into gene therapy manufacturing, it is picking up a couple of small vaccine production sites and a 100 employees.